Disease biology
Parkinson’s disease is characterized by progressive loss or dysfunction of dopamine-producing neurons, especially in the substantia nigra. Inflammation and insulin resistance are among the processes being studied for their potential roles in disease and symptom progression.
SUNRISE-PD
SUNRISE-PD (NE3107-PD-202) is a randomized, placebo-controlled Phase 2 study evaluating bezisterim in people with early Parkinson’s disease who had not yet been prescribed levodopa or other dopamine receptor agonists.
Research objective
The study evaluates whether modulating inflammation and insulin resistance can affect movement symptoms and other clinical measures. Results are needed before conclusions can be drawn about benefit or risk.
Development-stage information can change. Investigational candidates are not approved, and safety and efficacy have not been established. Review source documents and current regulatory disclosures.